Literature DB >> 16493254

Early diagnosis and predictors of malignancy of adnexal masses.

Eddie F C Murta1, Rosekeila S Nomelini.   

Abstract

PURPOSE OF REVIEW: Ovarian cancer is an important cause of death among women with a malignant gynecological tumor. Cure rates for the disease at an early stage are around 80-90%, but survival is only 50% as the majority of women already show advanced disease upon diagnosis. The combination of gynecological examination, ultrasonography, and systemic tumor marker assay is considered to be a good strategy for the early diagnosis of ovarian neoplasia. RECENT
FINDINGS: Today, new technologies such as ultrasonography and tumor marker assay have increased the diagnosis rate for adnexal masses. These non-invasive methods, however, frequently do not distinguish benign conditions from malignant ones, which results in unnecessary surgery. Transvaginal ultrasonography is useful for diagnosing adnexal masses, but benign and malignant adnexal masses can present similar morphological characteristics. Combination with color Doppler ultrasonography and/or tumor markers may improve the accuracy of the method. Gene-expression array, proteomics and mathematical models form new approaches, but proper prospective studies are needed to validate them.
SUMMARY: The techniques of pelvic examination, ultrasonography, color Doppler ultrasonography, and tumor markers can be indicated for the diagnosis of ovarian cancer. The differentiation between benign and malignant ovarian tumor is, however, a clinical challenge. Until better diagnostic methods become available, patients and their physicians can use these techniques to decide on management.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493254     DOI: 10.1097/01.gco.0000192967.67567.e9

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  7 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

3.  Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.

Authors:  Millena Prata Jammal; Allison Araújo DA Silva; Agrimaldo Martins Filho; Eliângela DE Castro Côbo; Sheila Jorge Adad; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

4.  Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors.

Authors:  Rosekeila Simões Nomelini; Lívia Carolina de Abreu Ribeiro; Beatriz Martins Tavares-Murta; Sheila Jorge Adad; Eddie Fernando Candido Murta
Journal:  Mediators Inflamm       Date:  2009-01-05       Impact factor: 4.711

5.  Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer.

Authors:  T D Santos; M P Jammal; T P Silveira; E F C Murta; R S Nomelini
Journal:  Pathologica       Date:  2019-06

6.  Parameters of blood count and tumor markers in patients with borderline ovarian tumors: a retrospective analysis and relation to staging.

Authors:  Rosekeila Simões Nomelini; Taísa Morete da Silva; Beatriz Martins Tavares Murta; Eddie Fernando Candido Murta
Journal:  ISRN Oncol       Date:  2012-04-17

7.  Cytokines and Prognostic Factors in Epithelial Ovarian Cancer.

Authors:  Millena Prata Jammal; Agrimaldo Martins-Filho; Thales Parenti Silveira; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Clin Med Insights Oncol       Date:  2016-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.